GlassScriptPhysician profile
Stephen Carney
NPI 1609815877
$4,711.89
in general payments reported to CMS, 2019-2025
41 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $656 · 2021: $611 · 2022: $843 · 2023: $880 · 2024: $799 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,295.73 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $528.80 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $294.68 | 2019-2024 | |
| Amgen INC. | $256.63 | 2022-2024 | Otezla, Repatha, Prolia |
| Glaxosmithkline, LLC. | $254.00 | 2020-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $159.18 | 2020-2024 | Mounjaro, Zepbound |
| Allergan, INC. | $149.44 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.62 | 2019-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.04 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $112.06 | 2021-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $101.34 | 2019-2025 | |
| Vertex Pharmaceuticals Incorporated | $86.93 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.16 | 2019-2022 | |
| Exact Sciences Corporation | $79.87 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $75.27 | 2022-2024 | Rexulti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Carney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.